Clinical Trials Browser

Phase 1/2 × ublituximab × Other hematologic neoplasm × Clear all

NCT01647971 2022-11-21

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02013128 2022-10-24

Ublituximab + Ibrutinib in Select B-cell Malignancies

Phase 1/2 Completed

66 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03379051 2022-08-22

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase 1/2 Terminated

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell